Navigation Links
Low vitamin D levels do not increase the risk of chronic obstructive pulmonary disease
Date:11/3/2011

Vitamin D levels are not related to acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in patients with severe COPD, according to a large prospective cohort study involving 973 North American patients. The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

In the study, a secondary analysis of data from a randomized, controlled trial of the effects of azithromycin on the frequency of AECOPD, no relationship was found between baseline Vitamin D levels and time to first AECOPD or between vitamin D levels and AECOPD exacerbation rates.

"Vitamin D insufficiency and deficiency are common in patients with COPD, and patients with severe COPD are at the highest risk for exacerbations, so we hypothesized that low vitamin D levels might increase the risk of AECOPDs," said Ken M. Kunisaki, M.D., of the Minneapolis Veterans Affairs Medical Center. "Our negative results are in contrast with earlier studies in which lower vitamin D levels were associated withhigher rates of respiratory infections in adults and more frequent asthma exacerbations in children."

In the current study, mean forced expiratory volume in one second (FEV1) was 1.12L, 40% of predicted. Mean vitamin D level at baseline was 25.7 12.8 ng/mL, with 33.1% of subjects categorized as vitamin D insufficient (≥20 ng/mLbut <30 ng/mL), 32.0% as vitamin D deficient (<20 ng/mL) and 8.4% as having severe vitamin D deficiency (<10 ng/mL).AECOPDs were defined as a complex of respiratory symptoms (increased or new-onset) of at least 1 of thefollowing: cough, sputum, wheezing, dyspnea, or chest tightness with a durationof at least 3 days and requiring treatment with an antibiotic or systemiccorticosteroid.

During 1 year of follow-up, study subjects experienced a total of 1415 AECOPDs. Of 973 patients,360 (37%)remained AECOPD-free, 278 (29%) had 1 AECOPD, 133 (14%)had 2 AECOPDs, and 202 (21%) had 3 or moreAECOPDs.

In the primary analysis, vitamin D levels had no relationship to time to first AECOPD; for a 10 ng/mL increment in vitamin D level, the estimated hazard ratio was 1.04 (95% confidence interval: 0.97-1.12). In secondary analyses, vitamin D levels were not related to annualized rates of AECOPDs in either Poisson (p=0.82)or negative binomial analyses (p=0.87).

Patients with severe vitamin D deficiency had a higher mean rateof AECOPDs, but this difference was not statistically significant. Patients with severe vitamin D deficiency did not exhibit faster time to first AECOPD than other patients.

The study had some limitations. Vitamin D levels were only assessed at baseline, and so may have changed during the study period. Seasonal changes in vitamin D levels may also have occurred.

"Contrary to what we expected, baseline vitamin D levelswere not related to the risk of subsequent AECOPDs in this large group of COPD patients at high risk of AECOPD," Dr. Kunisaki said. "Vitamin D supplementation is unlikely to have an effect on AECOPD risk in these patients."


'/>"/>
Contact: Nathanial Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Caucasians who avoid sun exposure more likely to be vitamin D deficient, Stanford study suggests
2. Low vitamin D common in spine surgery patients
3. Vitamin B-based treatment for corneal disease may offer some patients a permanent solution
4. Women do not get enough vitamin D during the menopause
5. Research Sheds Light on Vitamin Ds Role in Immunity
6. Extra Vitamin E May Be Associated With Prostate Cancer
7. National study finds vitamin E supplement may increase prostate cancer risk
8. Oral steroids linked to severe vitamin D deficiency in nationwide study
9. Could Too Little Vitamin B-12 Shrink the Aging Brain?
10. Many Black Men in Cold Climates Lack Vitamin D
11. Vitamin D deficiency linked with airway changes in children with severe asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very high-dynamic ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare ... device, was featured in a study indicating superior performance against competitive products in ... of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: ... by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, ... and poetry collections. , “I have been writing since high school and have ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Report Details What can be ... going to grow at the fastest rates? This visiongain ... trends, opportunities and prospects. Our 190-page report provides ... areas in the industry and the future market prospects. ... the all the major categories of the ophthalmic devices ...
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
Breaking Medicine Technology: